
A literature review of pandemic novel coronavirus disease 2019 and potential drugs treatment
Abstract
Keywords
References
Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Coronaviruses 2015;1282:1-23.
Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. Virology 2001;279:371-4.
Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401-2.
Novel Coronavirus (2019-nCoV) Situation Report 48. Available from: https://www.who.int/docs/defaultsource/ coronaviruse/situation-reports/20200308-sitrep-48-covid-19. pdf?sfvrsn=16f7ccef_4. [Last accessed on 2020 Mar 13].
Rismanbaf A. Potential treatments for COVID-19; a narrative literature review. Arch Acad Emerg Med 2020;8:e29.
Smith T, Bushek J, Prosser T. COVID-19 Drug Therapy Potential Options. Netherlands: Elsevier; 2020.
Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview. Infez Med 2020;28:174-84.
Özdemir Ö. Coronavirus disease 2019 (COVID-19): Diagnosis and management. Erciyes Med J 2020;42:242-7.
Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016;3:237-61.
Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020;52:56-65.
Zeng Q, Langereis MA, Van Vliet AL, Huizinga EG, De Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 2008;105:906-59.
Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic virus-a review. Front Immunol 2020;28:174–184.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, et al. Passive immunotherapy: Assessment of convalescent serum against Ebola virus Makona infection in nonhuman primates. J Infect Dis 2016;214:S367-74.
Shneider A, Kudriavtsev A, Vakhrusheva A. Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol 2020;39:153-62.
Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020;250:117583.
Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 2010;48:142-7.
Chang R, Sun WZ, Ng TB. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents 2020;56:106118.
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.
Ishikado A, Imanaka H, Takeuchi T, Harada E, Makino T. Liposomalization of lactoferrin enhanced it’s anti-inflammatory effects via oral administration. Biol Pharm Bull 2005;28:1717-21.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020;92:479-90.
Genentech. Actemra (Tocilizumab) Injection Package Insert. South San Francisco, CA: Genentech Inc.; 2019.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970-5.
Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit Cathepsin L in the late endosome/ lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 2016;291:9218-32.
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: An alternative drug for the treatment of COVID-19? Int J Antimicrob Agents 2020;55:105944.
Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV. New York: bioRxiv; 2020.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315-31.
McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: A review of early and emerging options. Open Forum Infect Dis 2020;7:ofaa105.
Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488-94.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;383:1787-99.
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583.
Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus 2020;12:e7560.
Carr AC. A new clinical trial to test high-dose Vitamin C in patients with COVID-19. Crit Care 2020;24:133.
Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of Vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: The CITRIS-ALI randomized clinical trial. JAMA 2019;322:1261-70.
Paprocki M. Nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 patient. Disaster Emerg Med J 2020;5:108-9.
González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J 2008;10:42-6.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDAAPPROVED drug ivermectin inhibits the replication of sarscov- 2 in vitro. Antiviral Res 2020;178:104787.
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.
Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis 2020;90:1289.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.
Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019;43:101300.
Refbacks
- There are currently no refbacks.